Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment

Leukemia

Volumn 29, Issue 1, 2015, Pages 230-232

  Yeung, D T ^a,b,c   Moulton, D J ^a,c,d   Heatley, S L ^d   Nievergall, E ^d   Dang, P ^d   Braley, J ^b   Branford, S ^b   Moore, S ^b   Mullighan, C G ^a,d,e   Hughes, T P ^a,c,d   White, D L ^a,d,f  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c SA Pathology ^*  (Australia)

^d South Australia Health Medical Research Institute   (Australia)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABL 1 KINASE; BCR ABL 1 PROTEIN; BCR ABL PROTEIN; DASATINIB; DEXAMETHASONE; METHOTREXATE; PHOSPHOTRANSFERASE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG PULSE THERAPY; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; LETTER; MALE; MASS SPECTROMETRY; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; VERY ELDERLY; GENETICS; MUTATION; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE;

FUSION PROTEINS, BCR-ABL; HUMANS; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; RECURRENCE; THIAZOLES;

EID: 84920680742     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.256     Document Type: Letter

References (15)

1. Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014; 123: 843-850.
2. Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T. T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. Anticancer Res 2012; 32: 1779-1783.
3. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
4. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
5. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-166.
6. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. ASH Educ Program Book 2012; 2012: 389-396.
7. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D et al. Targetable kinase activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371: 1005-1015.
8. Weston BW, Hayden MA, Roberts KG, Bowyer S, Hsu J, Fedoriw G et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 2013; 31: e413-e416.
9. Loh ML, Zhang J, Harvey RC, Roberts K, Payne-Turner D, Kang H et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood 2013; 121: 485-488.
10. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-1796.
11. Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol 2011; 29: 4250-4259.
12. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25: 7-22.
13. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029.
14. Ernst T, Hochhaus A. Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 2012; 39: 58-66.
15. Hochhaus A, La Rosee P, Muller MC, Ernst T, Cross NC. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011; 10: 250-260.